Talaris tries out public markets

Talaris Therapeutics, a US-based cell therapy developer spun out of University of Louisville, has filed for a $100m initial public offering on the Nasdaq Global Market.
The company, which previously operated as Regenerex, has yet to set any terms for the proposed offering.
Founded in 2002, Talaris is developing cell therapies that help prevent the rejection of transplanted organs and eliminate the need for immunosuppression medication for organ transplant patients.
Its lead candidate therapy, FCR001, is aimed at inducing immune system tolerance in living donor kidney transplant patients.
Talaris would use the proceeds to support the advancement of FCR001 through a phase 3 registration trial. The funding would also support research and development activities and general corporate purposes.
Talaris raised $115m in a series B round in October 2020 that was co-led by Surveyor Capital and Viking Global Investors with participation from Cormorant Asset Management, Invus, funds and accounts managed by BlackRock, Eventide Asset Management, Logos Capital, Aisling Capital and Pamoja Capital.
Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA also backed the series B round after participating in a $100m series A round in April 2019.
Blackstone is the largest shareholder in the business with a 24.9% stake, while other notable shareholders include Longitude (9.2%), Qiming (8.8%), Citadel (7.8%) and Viking Global (7.8%).
Morgan Stanley, SVB Leerink, Evercore and Guggenheim Securities are joint-bookrunners for the IPO.